127 related articles for article (PubMed ID: 35081345)
1. Endothelial p130cas confers resistance to anti-angiogenesis therapy.
Wen Y; Chelariu-Raicu A; Umamaheswaran S; Nick AM; Stur E; Hanjra P; Jiang D; Jennings NB; Chen X; Corvigno S; Glassman D; Lopez-Berestein G; Liu J; Hung MC; Sood AK
Cell Rep; 2022 Jan; 38(4):110301. PubMed ID: 35081345
[TBL] [Abstract][Full Text] [Related]
2. Targeting CXCR4-dependent immunosuppressive Ly6C
Jung K; Heishi T; Incio J; Huang Y; Beech EY; Pinter M; Ho WW; Kawaguchi K; Rahbari NN; Chung E; Kim JK; Clark JW; Willett CG; Yun SH; Luster AD; Padera TP; Jain RK; Fukumura D
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10455-10460. PubMed ID: 28900008
[TBL] [Abstract][Full Text] [Related]
3. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
[TBL] [Abstract][Full Text] [Related]
4. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
Nick AM; Stone RL; Armaiz-Pena G; Ozpolat B; Tekedereli I; Graybill WS; Landen CN; Villares G; Vivas-Mejia P; Bottsford-Miller J; Kim HS; Lee JS; Kim SM; Baggerly KA; Ram PT; Deavers MT; Coleman RL; Lopez-Berestein G; Sood AK
J Natl Cancer Inst; 2011 Nov; 103(21):1596-612. PubMed ID: 21957230
[TBL] [Abstract][Full Text] [Related]
5. Vascular Endothelial Growth Factor (VEGF) Promotes Assembly of the p130Cas Interactome to Drive Endothelial Chemotactic Signaling and Angiogenesis.
Evans IM; Kennedy SA; Paliashvili K; Santra T; Yamaji M; Lovering RC; Britton G; Frankel P; Kolch W; Zachary IC
Mol Cell Proteomics; 2017 Feb; 16(2):168-180. PubMed ID: 28007913
[TBL] [Abstract][Full Text] [Related]
6. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
[TBL] [Abstract][Full Text] [Related]
7. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
[TBL] [Abstract][Full Text] [Related]
8. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
Eguchi R; Kawabe JI; Wakabayashi I
J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
[TBL] [Abstract][Full Text] [Related]
9. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
[TBL] [Abstract][Full Text] [Related]
10. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
11. Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells.
Evans IM; Yamaji M; Britton G; Pellet-Many C; Lockie C; Zachary IC; Frankel P
Mol Cell Biol; 2011 Mar; 31(6):1174-85. PubMed ID: 21245381
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Dana P; Fujikawa S; Matsuda K; Ohkuma K; Kudo E; Kraiklang R; Wongkham C; Wongkham S; Okada S
Tumour Biol; 2016 Jul; 37(7):9023-35. PubMed ID: 26762407
[TBL] [Abstract][Full Text] [Related]
13. Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.
Bannoud N; Stupirski JC; Cagnoni AJ; Hockl PF; Pérez Sáez JM; García PA; Mahmoud YD; Gambarte Tudela J; Scheidegger MA; Marshall A; Corrie PG; Middleton MR; Mariño KV; Girotti MR; Croci DO; Rabinovich GA
Proc Natl Acad Sci U S A; 2023 Jan; 120(3):e2214350120. PubMed ID: 36634146
[TBL] [Abstract][Full Text] [Related]
14. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
Gao F; Yang C
Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
[TBL] [Abstract][Full Text] [Related]
16. p130Cas scaffolds the signalosome to direct adaptor-effector cross talk during Kaposi's sarcoma-associated herpesvirus trafficking in human microvascular dermal endothelial cells.
Bandyopadhyay C; Veettil MV; Dutta S; Chandran B
J Virol; 2014 Dec; 88(23):13858-78. PubMed ID: 25253349
[TBL] [Abstract][Full Text] [Related]
17. Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells.
Willis CD; Poluzzi C; Mongiat M; Iozzo RV
FEBS J; 2013 May; 280(10):2271-84. PubMed ID: 23374253
[TBL] [Abstract][Full Text] [Related]
18. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF.
Endo A; Fukuhara S; Masuda M; Ohmori T; Mochizuki N
J Recept Signal Transduct Res; 2003; 23(2-3):239-54. PubMed ID: 14626450
[TBL] [Abstract][Full Text] [Related]
20. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).
Mitamura T; Pradeep S; McGuire M; Wu SY; Ma S; Hatakeyama H; Lyons YA; Hisamatsu T; Noh K; Villar-Prados A; Chen X; Ivan C; Rodriguez-Aguayo C; Hu W; Lopez-Berestein G; Coleman RL; Sood AK
Oncogene; 2018 Feb; 37(6):722-731. PubMed ID: 29059175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
